Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. J of Skin 2018, 2 (S1), S45. https://doi.org/10.25251/skin.2.supp.45.